-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] At present, the annual transcripts of listed Chinese medicine companies have been announced one after anoth.
As of April 30, about 71 companies have disclosed their 2021 annual report da.
In 2021, they will achieve a total operating income of 335 billion yuan and a net profit of 37 billion yu.
Among the 71 companies, more than half of them achieved profitability, of which 47 companies saw profit growth and 24 companies declin.
Among them, the companies that have doubled their performance, including Baiyunshan, Yunnan Baiyao, China Resources Sanjiu, Pien Tze Huang, e.
, and 5 companies whose net profit has increased by over 100% are Dong E E Jiao, Kang Enbei, *ST Kangmei, Jianmin Group , Tas.
In the first quarter of 2022, the overall performance of these five companies will still maintain grow.
Dong’e Ejiao: Net profit increased by over 917% The annual report shows that in 2021, Dong’e Ejiao’s revenue will be 85 billion, a year-on-year increase of 189%; net profit will be 440 million, a year-on-year increase of 914
It is reported that the company adheres to customer-centricity, focuses on customer growth and retention, accelerates product innovation, strengthens the transformation of scientific research results, and continuously releases brand productivity to achieve stable and healthy grow.
It is worth mentioning that in 2022, the company's performance will continue to gr.
In the first quarter of 2022, it will achieve revenue of 890 million yuan, a year-on-year increase of 2
The net profit attributable to shareholders of the listed company is 115 million yuan, a year-on-year increase of 80
Conba: Net profit rose by more than 343% According to Conba's annual report, in 2021, it will achieve operating income of 15 billion yuan, a year-on-year increase of 4%; net profit is 009 billion yuan, a year-on-year increase of 34
For the substantial increase in net profit, Kang Enbei said that the main reason is the large investment income brought by the company's transfer of 42% equity of its subsidiary, Zhenshiming, at the end of 202Recently, the company also announced its Q1 financial report for fiscal year 202Data show that during the reporting period, Conba’s revenue reached 595 billion yuan, an increase of 23% compared with 591 billion yuan in the same period last year;*ST Kangmei: Net profit rose by more than 125% *ST Kangmei's financial report disclosed that the company's annual revenue was 153 billion yuan, a year-on-year decrease of 227%; the net profit attributable to the parent was 918 billion yuan, a year-on-year increase of 124
The company's first-quarter results announcement released on the evening of April 29 shows that in the first quarter of 2022, the company achieved revenue of 934 million yuan, a year-on-year decrease of 115%; net profit attributable to the parent was -114221 million yuan, a year-on-year increase of 82
Jianmin Group: Net profit exceeded 119% Jianmin Group's revenue was 278 billion yuan, a year-on-year increase of 348%, and the net profit attributable to shareholders of listed companies was 325 million yuan, a year-on-year increase of 117
From the perspective of revenue composition, the pediatric business is its main source of reven.
In 2021, the revenue in this field will be 890 million yuan, a year-on-year increase of 4
According to the 2022 first quarter report, the company's main income was 918 million yuan, up 1% year-on-year; the net profit attributable to the parent was 87092 million yuan, up 295% year-on-ye.
Tasly: Net profit exceeds 109% Tasly's 2021 annual report shows that the company's main income is 952 billion yuan, a year-on-year decrease of 443%; the net profit attributable to the parent is 359 billion yuan, a year-on-year increase of 105
In the first quarter of 2022, the company achieved a total operating income of 87 billion yuan, a year-on-year increase of 6%; net profit attributable to the parent was -560 million, compared with 320 million yuan in the same period last year, failing to maintain a profitable sta.
However, the company's pharmaceutical industry revenue increased by 01%, deducting non-net profit of 231 milli.
It is reported that the sharp drop in the company's net profit attributable to the parent in the first quarter of this year was mainly due to the decline in the fair value of financial assets, which did not affect the company's actual business operatio.
The decrease in net profit attributable to the parent company was mainly due to the significant decrease in the fair value of financial assets such as I-MAB and Keji Pharmaceutical held by the compa.
The company's main business has not been actually affect.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
As of April 30, about 71 companies have disclosed their 2021 annual report da.
In 2021, they will achieve a total operating income of 335 billion yuan and a net profit of 37 billion yu.
Among the 71 companies, more than half of them achieved profitability, of which 47 companies saw profit growth and 24 companies declin.
Among them, the companies that have doubled their performance, including Baiyunshan, Yunnan Baiyao, China Resources Sanjiu, Pien Tze Huang, e.
, and 5 companies whose net profit has increased by over 100% are Dong E E Jiao, Kang Enbei, *ST Kangmei, Jianmin Group , Tas.
In the first quarter of 2022, the overall performance of these five companies will still maintain grow.
Dong’e Ejiao: Net profit increased by over 917% The annual report shows that in 2021, Dong’e Ejiao’s revenue will be 85 billion, a year-on-year increase of 189%; net profit will be 440 million, a year-on-year increase of 914
It is reported that the company adheres to customer-centricity, focuses on customer growth and retention, accelerates product innovation, strengthens the transformation of scientific research results, and continuously releases brand productivity to achieve stable and healthy grow.
It is worth mentioning that in 2022, the company's performance will continue to gr.
In the first quarter of 2022, it will achieve revenue of 890 million yuan, a year-on-year increase of 2
The net profit attributable to shareholders of the listed company is 115 million yuan, a year-on-year increase of 80
Conba: Net profit rose by more than 343% According to Conba's annual report, in 2021, it will achieve operating income of 15 billion yuan, a year-on-year increase of 4%; net profit is 009 billion yuan, a year-on-year increase of 34
For the substantial increase in net profit, Kang Enbei said that the main reason is the large investment income brought by the company's transfer of 42% equity of its subsidiary, Zhenshiming, at the end of 202Recently, the company also announced its Q1 financial report for fiscal year 202Data show that during the reporting period, Conba’s revenue reached 595 billion yuan, an increase of 23% compared with 591 billion yuan in the same period last year;*ST Kangmei: Net profit rose by more than 125% *ST Kangmei's financial report disclosed that the company's annual revenue was 153 billion yuan, a year-on-year decrease of 227%; the net profit attributable to the parent was 918 billion yuan, a year-on-year increase of 124
The company's first-quarter results announcement released on the evening of April 29 shows that in the first quarter of 2022, the company achieved revenue of 934 million yuan, a year-on-year decrease of 115%; net profit attributable to the parent was -114221 million yuan, a year-on-year increase of 82
Jianmin Group: Net profit exceeded 119% Jianmin Group's revenue was 278 billion yuan, a year-on-year increase of 348%, and the net profit attributable to shareholders of listed companies was 325 million yuan, a year-on-year increase of 117
From the perspective of revenue composition, the pediatric business is its main source of reven.
In 2021, the revenue in this field will be 890 million yuan, a year-on-year increase of 4
According to the 2022 first quarter report, the company's main income was 918 million yuan, up 1% year-on-year; the net profit attributable to the parent was 87092 million yuan, up 295% year-on-ye.
Tasly: Net profit exceeds 109% Tasly's 2021 annual report shows that the company's main income is 952 billion yuan, a year-on-year decrease of 443%; the net profit attributable to the parent is 359 billion yuan, a year-on-year increase of 105
In the first quarter of 2022, the company achieved a total operating income of 87 billion yuan, a year-on-year increase of 6%; net profit attributable to the parent was -560 million, compared with 320 million yuan in the same period last year, failing to maintain a profitable sta.
However, the company's pharmaceutical industry revenue increased by 01%, deducting non-net profit of 231 milli.
It is reported that the sharp drop in the company's net profit attributable to the parent in the first quarter of this year was mainly due to the decline in the fair value of financial assets, which did not affect the company's actual business operatio.
The decrease in net profit attributable to the parent company was mainly due to the significant decrease in the fair value of financial assets such as I-MAB and Keji Pharmaceutical held by the compa.
The company's main business has not been actually affect.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
